Home » FDA Grants Priority Review for Nexavar in Thyroid Cancer
FDA Grants Priority Review for Nexavar in Thyroid Cancer
August 28, 2013
The FDA has granted Nexavar, a collaboration between Onyx and Bayer, priority review status, placing the drug a step closer to being approved to treat thyroid cancer.
Pharma Times
Pharma Times
Upcoming Events
-
21Oct